AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. announced plans to separate into two independent, publicly traded entities: "Royalty Management Co," which will manage existing royalty streams including Jemperli from GSK (reporting $262 million in Q2 2025 sales and guided for $2.7 billion peak sales) and imsidolimab from Vanda Pharmaceuticals, and "Biopharma Co," focused on developing clinical-stage autoimmune and inflammatory therapeutics like rosnilimab. This strategic move, anticipated to be completed by year-end 2026 with Biopharma Co funded for at least two years, aims to align investor interests with distinct business models and resulted in AnaptysBio's stock (ANAB) rising nearly 29% on the news.

Analysis

AnaptysBio's plan to separate into two publicly traded companies has been met with significant market approval, evidenced by a 28.95% surge in its stock price. The strategic rationale is to create two pure-play entities, allowing investors to align with distinct risk-return profiles. 'Royalty Management Co' will be a de-risked, cash-flow-focused vehicle holding valuable royalty rights on GSK's Jemperli, which reported $262 million in Q2 2025 sales and is guided for approximately $2.7 billion in peak sales. This entity also holds rights to potential milestones and a 10% royalty on Vanda's imsidolimab, which has a near-term catalyst with a BLA submission expected in H2 2025. Conversely, 'Biopharma Co' will operate as a clinical-stage development company, carrying higher risk and growth potential. Its lead asset is rosnilimab, with a key data catalyst from its Phase 2 ulcerative colitis trial expected in late 2025. The new Biopharma Co will be funded for at least two years, mitigating immediate financing concerns, though uncertainty remains regarding the final allocation of rosnilimab's economic value pending a potential global partnership. The entire separation process is projected to conclude by year-end 2026, creating a long-term event path for investors.

Key Decisions for Investors

• Investors should conduct a sum-of-the-parts valuation, separately assessing the net present value of the predictable cash flows from Royalty Management Co and the risk-adjusted value of Biopharma Co's clinical pipeline.
• Monitor key upcoming catalysts that will directly impact the valuation of the successor companies, specifically the topline data for rosnilimab in late 2025 and any news on a strategic partnership for the asset.
• Current shareholders should determine which of the two resulting business profiles—a stable royalty stream or a high-growth R&D venture—aligns with their investment strategy ahead of the planned 2026 separation.
• Factor in the considerable execution risk associated with a complex, two-year corporate separation and the noted uncertainty regarding the final economic split of the rosnilimab asset between the two new entities.